A total of 31 adult patients with AML entered in the EORTC/ GIMEMA AML-10 trial, who received autologous stem cell transplantation (ASCT) after induction and consolidation chemotherapy, were prospectively evaluated for minimal residual disease (MRD) by multidimensional flow cytometry (MFC). Using a cutoff level of 3.5 Â 10 À4 leukemic cells pre-ASCT, 12 patients (39%) were stratified to MRD high-risk group and 19 (61%) into MRD low-risk group. During follow-up, all patients who were in the high-risk group relapsed at a median time of 7 months; in the low-risk group, five patients relapsed at a median time of 11 months and 14 remained in remission for 56 (range 7-80) months (P ¼ 0.00004). Longitudinal MFC determinations post-ASCT showed increased MRD levels in three of the five patients who underwent subsequent relapse, while disease recurrence was unpredicted in the remaining two cases. The pre-ASCT MRD status was the factor most strongly associated with relapse risk in the multivariate analysis (P ¼ 0.0014). We conclude that: (1) pre-ASCT MRD status predicts successful outcome in patients receiving ASCT; (2) high-dose chemotherapy conditioning regimen followed by ASCT has no impact on the unfavorable prognostic value of high pre-ASCT MRD level; and (3) sequential MRD monitoring post-ASCT may allow the prediction of impending relapse.
Introduction
A number of reports have established the feasibility of minimal residual disease (MRD) assessment by multidimensional flow cytometry (MFC) in acute leukemia and the clinical value of this approach for predicting patient response to therapy and outcome. [1] [2] [3] [4] [5] [6] [7] We and others recently reported that the level of MRD after consolidation/intensification is an important prognosticator in acute myeloid leukemia (AML) patients treated with intensive chemotherapy. 4, 6 In particular, our group observed that, compared to patients with lower MRD levels, patients with X3.5 Â 10 À4 residual leukemic cells after consolidation had a significantly higher relapse rate. 6, 7 In such studies, we reported preliminarily that autologous stem cell transplantation (ASCT) did not apparently impact on the unfavorable significance of high pre-ASCT MRD levels. In the present study, we expand this preliminary observation by focusing on 31 homogeneously treated adult AML patients, who underwent ASCT in the context of the EORTC/GIMEMA AML10 protocol. All the patients were prospectively analyzed by MFC at regular pre-established time points before and after ASCT. Our results highlight the prognostic value of pre-ASCT MRD assessment by MFC in this therapeutic context.
Patients and methods

Patients and treatment
Approval for this study was obtained from the institutional review board. The criteria for inclusion were: (1) diagnosis of AML other than APL; (2) expression of 'leukemia-associated' phenotype; (3) eligibility for intensive chemotherapy; and (4) achievement of a morphologic complete remission (CR) after induction therapy. A given phenotype was regarded as 'leukemia-associated' when it resulted from asynchronous antigen expression, cross-lineage antigen expression, antigen overexpression, and aberrant light-scatter properties. 4, 8, 9 From a total of 51 adult AML patients consecutively enrolled at our Institution in the EORTC/GIMEMA AML10 protocol between November 1994 and December 1999, 44 were eligible for ASCT. Of these, 35 (79%) showed a leukemia-associated phenotype at diagnosis; 31 (89%) survived induction and consolidation and were followed up for MRD monitoring before and after the transplant procedure. The main clinicobiological characteristics of these patients at diagnosis are shown in Table 1 .
The EORTC/GIMEMA AML10 randomized trial included patients aged 18-60 years. Induction treatment consisted of cytarabine (100 mg/m 2 c.i. day 1-10), etoposide (100 mg/m 2 day 1-5), and, on days 1, 3, and 5, either daunorubicin (50 mg/m 2 ), mitoxantrone (12 mg/m 2 ) or idarubicin (10 mg/m 2 ) according to random assignment. As consolidation, patients received cytarabine (500 mg/m 2 /q12 h days 1-6) and the same anthracycline given in induction, on days 4-6. All patients with confirmed morphological CR at the postconsolidation evaluation, who did not have an HLA-compatible sibling, were randomly assigned to receive autologous peripheral blood (APBSCT) or bone marrow stem cell transplantation (ABMSCT); patients with an HLAcompatible sibling were given allograft (de Witte et al, Blood, 2001; 98: 3565). For patients randomized in the ABMSCT arm, the required criterion for the BM harvest to be used for autografting was the collection of a minimum of 1 Â 10 8 /kg nucleated cells and X1 Â 10 6 CD34 þ cells/kg. For patients randomized in the APBSCT arm, the peripheral harvest should have contained at least 2 Â 10 6 CD34 þ cells/kg. The patients were to undergo the transplant procedure within a maximum of 6 months from the achievement of CR. The pretransplant regimen consisted of busulphan (4 mg/kg on days À8, À7, À6, À5) and cyclophosphamide (60 mg/kg on days À4 and À3), with autologous stem cell reinfusion on day 0. median time elapsed from the completion of consolidation to ASCT was 2.4 months, an additional control of patient MRD status was planned in all cases immediately before the administration of conditioning regimen for ASCT. At diagnosis, studies were performed on erythrocyte-lysed whole BM samples, using a broad panel of monoclonal antibodies targeting membrane antigens, as previously described. 6, 7 Briefly, each antibody was incubated with 1-2 Â 10 6 cells in 100 ml volume and isotype-matched antibodies were used as negative controls. After 10 min incubation, 2 ml of FACS lysing solution (BectonDickinson) was added and the sample incubated for another 10 min. After two washings in PBS, cells were resuspended in 0.5 ml of PBS and analyzed with a flow cytometer (Facsort Becton Dickinson, Mountain View, CA, USA). Cases displaying aberrant phenotypes were selected and reinvestigated by staining with the (triple/quadruple) relevant combinations of antibodies. A given combination of markers was regarded as relevant if expressed in 450% of the blasts. This step served to define a patient's 'immunologic fingerprint', which in turn was used to reveal the persistence of residual leukemic cells during subsequent follow-up. At least two antibody combinations for each case were used to minimize pitfalls due to 'phenotypic switches'. The CellQuest (Becton Dickinson) software was used for the flow-cytometric data acquisition, applying a 'multiparametric live gate' on the forward-light/orthogonal light scatter and fluorescence plots. Samples were then analyzed by using the PAINT-A-GATE PRO software program (Becton Dickinson), as previously described in detail. 6 MRD studies during remission were performed on erythrocyte-lysed whole BM samples using the same association of antibodies defining the 'immunologic fingerprint' of each patient. During data acquisition, a live gate including the lymphomonocytic/granuloblastic region and excluding debris and platelet aggregates was used with 10 6 total events acquired in all samples. The acquired events were analyzed with the PAINT-A-GATE software, as detailed elsewhere. 6 
Statistical analysis
The relationship of MRD to the relapse rate was estimated by two-sided w 2 test (or Fisher's exact test when either group included fewer than 20 cases). A P-value of 0.05 or less was considered to be significant. The median test of Kruskal-Wallis was used to assess the relationship between the level of MRD after induction and before ASCT, as well as between the number of mononuclear and CD34 þ cells in MRD þ vs MRD À patients. The Kaplan-Meier method was used for estimation of posttransplant survival (PT-SV) and relapse-free survival (PT-RFS). 10 For the comparison of survival and remission duration of two or more groups, the log-rank test was applied. CR and relapse were defined by standardized criteria. 11 PT-SV and PT-RFS were calculated from the date of stem cell re-infusion to the date of death or last follow-up, or until relapse, respectively. To evaluate the simultaneous impact of different variables on relapse rate and duration of PT-SV and PT-RFS, a multivariate analysis was performed using a stepwise regression model.
Results
According to our previous experience, 6, 7 we defined two categories of risk based on the number of patient's residual leukemic cells o(low risk) or X(high risk) 3.5 Â 10 À4 at the end of consolidation therapy. Therefore, in the following sections, patients with o3.5 Â 10 À4 residual malignant cells will be referred to as MRD low risk, whereas those with X3.5 Â 10
À4
residual malignant cells will be referred to as MRD high risk.
Determination of MRD before ASCT
Out of 31 (35%) patients, 11 were in the MRD high-risk group at the end of consolidation therapy (median no. of residual leukemic cells ¼ 3.7 Â 10 À3 , range 4 Â 10 À4 -2.3 Â 10 À2 ); the remaining 20 (65%) were in the MRD low-risk group (median no. of residual leukemic cells ¼ 4.3 Â 10 À5 , range 0-3.4 Â 10 À4 ). Since the median time from the completion of consolidation to ASCT was 2.4 months, MRD was investigated again within 7-10 days before conditioning regimen was initiated, in order to confirm the individual MRD status observed at the hematological recovery after consolidation. At this stage, we found that in one case the level of MRD had shifted from a negative to a positive status; therefore, we had 12 MRD high-risk patients (median no. of residual leukemic cells ¼ 5.9 Â 10 À3 , range 6 Â 10 À4 -2.7 Â 10 À2 ) and 19 MRD low-risk patients (median no. of residual leukemic cells ¼ 5 Â 10 À5 , range 0-3.1 Â 10 À4 ). Thus, the MRD high-and low-risk patients approached the transplant procedure having 2 log difference in the amount of residual leukemia (P ¼ 0.000004). As a further step of analysis, we went back to the level of MRD as detected after induction therapy, to verify whether significant differences could exist at this stage between MRD high-and low-risk patients. We found out that, after induction, patients labeled as MRD high-risk pre-ASCT had a median number of residual leukemic cells of 3.8 Â 10 À3 (range 2 Â 10
), whereas those defined as MRD low-risk pre-ASCT had a median of 1.2 Â 10 À4 leukemic cells (range 0-3.1 Â 10 À4 ) (P ¼ 0.018). 
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Thus, patients in a low-risk situation showed 1 log less residual leukemic cells after induction and 2 logs less immediately before ASCT than patients who were in the MRD high-risk group; in the latter, the level of MRD had remained constant throughout the entire therapeutic process.
Determination of MRD after ASCT
Eight patients received BM stem cells and 23 PB stem cells, and upon full hematological recovery after transplant, MRD was investigated again. At this stage, we found that all of the 12 patients who were in the MRD high-risk group pre-ASCT tested again positive (median no. of residual leukemic cells 2.3 Â 10 À3 , range 6 Â 10 À4 -3 Â 10 À2 ). Moreover, the scheduled controls performed every 3 months from ASCT never disclosed conversion to a low-risk status in this group. All the 19 patients who were in the MRD low-risk group before ASCT tested negative on the first evaluation after ASCT; successive determinations showed an increase of the level of MRD in three patients who experienced subsequently hematological relapse. The kinetics of MRD expansion followed a similar pattern in these three cases. In fact, as shown in Figure 1 , the MRD low-risk status detected early after ASCT was followed 3 months later by a 2-3 logs increase, leading these patients to enter a high-risk status, which remained unaltered until overt relapse occurred after 7, 10, and 34 months, respectively. In the other 16 cases, the sequential tests never demonstrated raising levels of MRD; two patients in this group had a relapse after 11 and 12 months from ASCT, respectively, and 14 patients remained in continuous CR for a median time of 56 months (range 7-80). 
MRD status and clinical outcome
Overall, 17 of 31 (55%) patients had a relapse; when the analysis was broken down according to the MRD status, we observed that 100% (12/12) of the high-risk patients had a relapse vs 26% (5/19) of those who were in the MRD low-risk group (P ¼ 0.00004). The duration of PT-SV and PT-RFS was also significantly associated with the level of MRD before ASCT. In fact, patients in the MRD high-risk group had a median PT-SV of 12.9 months vs 49 months for those in the MRD low-risk group (P ¼ 0.006; Figure 2a) . Likewise, the median PT-RFS was 7 and 48 months for the MRD high-risk and MRD low-risk group, respectively (P ¼ 0.007; Figure 2b) . Finally, all relevant prognostic variables such as French-American-British classification, white blood cell count, multi-drug resistance-1 phenotype, karyotype, and MRD status were pooled into a multivariate model to determine their role as independent prognosticators. This analysis showed that pre-ASCT MRD high-risk status independently affected the frequency of relapse (P ¼ 0.0014), duration of PT-SV (P ¼ 0.02), and of PT-RFS (P ¼ 0.012).
Discussion
In this study, we found that sequential MRD determinations by MFC are clinically relevant in AML patients receiving high-dose chemotherapy followed by ASCT. Although there is no consensus about the optimal postremission therapy, 12 ASCT is presently regarded as one of the standard approaches for AML patients [13] [14] [15] [16] [17] and, to our knowledge, no study dealing with the role of MRD detection by MFC in patients undergoing ASCT has been published so far. Moreover, although the series hereby Figure 1 Kinetic of MRD expansion in three MRD low-risk patients who relapsed after ASCT. In the three cases shown in the figure, the MRD À status converted to a positive one after 3 months from the basal control performed soon after ASCT. This transition was quite abrupt, since in 3 months the level of MRD gained 2-3 cell logs. Afterwards, all the three patients had a hematological relapse (HR), although at variable time points from ASCT. reported is relatively small, the study comprises a homogeneously treated cohort of patients that was analyzed prospectively at pre-established time intervals, and by means of a wellstandardized method. As shown in several studies, such an approach allows to identify a leukemia-associated phenotypic profile in at least 70% of the AML patients. [4] [5] [6] [7] [8] We observed here that the pre-ASCT MRD status was a strong predictor of successive outcome in patients receiving ASCT, and that the high-dose conditioning chemotherapy had no impact on the unfavorable prognostic value of high pre-ASCT MRD level. Patients in the high-risk group, as assessed in the pre-ASCT evaluation, remained MRD positive several months after transplant, and all underwent disease recurrence within a median time of 7 months, also excluding the possibility of a late clearance effect of the transplant procedure. Thus, high levels of MRD are indicative of a status of incomplete remission where, by virtue of combined mechanisms of chemoresistance, a consistent number of leukemic cells survive chemotherapy; in this context, high-dose chemotherapy, conditioning regimen, and ASCT did not provide any additional benefit in terms of tumor killing. Interestingly, in the MRD high-risk group, the number of leukemic cells identified before and after ASCT did not significantly differ from that detected after induction and consolidation therapy. This indicates that patients with poor prognosis may be identified prematurely, and that they will most likely not benefit from this type of postremission therapy. In this view, the issue of whether and when additional or alternative treatments for MRD high-risk patients are needed is critical: drugs such as mylotarg seem promising candidates for 'in vivo' purging. 18 Likewise, IL-2 has proven effective in situations of limited (BM) blast infiltration so that it might be useful in MRD high-risk conditions. 19 Our experience is reminiscent of that described by Meloni et al 20 in acute promyelocytic leukemia (APL). By using RT-PCR of PML/RARa to determine the pretransplant MRD status in patients undergoing ABMSCT in second CR, these authors showed that the pretransplant molecular status was a strong predictor of successive outcome, as 7/7 patients in the PCR þ group persisted positive and relapsed during post-transplant follow-up, whereas 6/8 patients who had tested PCR À pre-ABMSCT experienced prolonged molecular and clinical remission. Based on these observations, the authors recommended to avoid the use of ABMSCT for APL patients with persistent PCR-detectable MRD after induction and consolidation therapy. 20 Since it was recently pointed out that patients with high 'mobilizing capacity' are at high risk of relapse probably due to the collection of a large number of leukemic cells following G-CSF priming, 21 we looked at the number of mononuclear and CD34 þ cells/kg reinfused in patients belonging to the PSCT arm. This analysis did not show significant differences between the group of MRD high-and low-risk patients, thus underscoring the prognostic value of residual disease 'in vivo'.
We were also interested in analyzing the small group of five patients who had a relapse although they belonged to the MRD low-risk category. Importantly, in none of these five patients were phenotypic switches observed at the time of hematological relapse. In three of them, disease recurrence was preceded by an abrupt increase of MRD levels. This finding suggests that, in some low-risk patients, the absence of detectable MRD is not genuine, owing to the presence of leukemic cells below the sensitivity threshold of the technique. It may be hypothesized that, as long as patients are on therapy, these low MRD levels are kept under control and result in abrupt expansion, leading to relapse once the therapy is ceased. This assumption may explain why in two cases a straightforward hematological relapse was not predicted, and raises the issue of the correct timing for MRD determination. It is conceivable that more frequent sampling in the post-ASCT outcome may result in enhanced detection of impending relapse.
In conclusion, although further studies in larger trials are warranted to confirm our findings, we highlight the clinical value of MRD evaluation by MFC in AML patients as a guide to treatment, and in particular for the choice of ASCT as postremission strategy.
